Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels

Détails

ID Serval
serval:BIB_3F9A6F6C062A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels
Périodique
J Clin Endocrinol Metab
Auteur(s)
Giraudet A. L., Vanel D., Leboulleux S., Auperin A., Dromain C., Chami L., Ny Tovo N., Lumbroso J., Lassau N., Bonniaud G., Hartl D., Travagli J. P., Baudin E., Schlumberger M.
ISSN-L
0021-972X (Print)0021-972X (Linking)
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
92
Numéro
11
Pages
4185-90
Langue
anglais
Notes
Giraudet, Anne LaureVanel, DanielLeboulleux, SophieAuperin, AnneDromain, ClarisseChami, LindaNy Tovo, NoelLumbroso, JeanLassau, NathalieBonniaud, GuillaumeHartl, DanaTravagli, Jean-PaulBaudin, EricSchlumberger, MartinengResearch Support, Non-U.S. Gov't2007/08/30 09:00J Clin Endocrinol Metab. 2007 Nov;92(11):4185-90. Epub 2007 Aug 28.
Résumé
PURPOSE: Because calcitonin level remains elevated after initial treatment in many medullary thyroid carcinoma (MTC) patients without evidence of disease in the usual imaging work-up, there is a need to define optimal imaging procedures. PATIENTS AND METHODS: Fifty-five consecutive elevated calcitonin level MTC patients were enrolled to undergo neck and abdomen ultrasonography (US); neck, chest, and abdomen spiral computed tomography (CT); liver and whole-body magnetic resonance imaging (MRI); bone scintigraphy; and 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/CT scan (PET). RESULTS: Fifty patients underwent neck US, CT, and PET, and neck recurrence was demonstrated in 56, 42, and 32%, respectively. Lung and mediastinum lymph node metastases in the 55 patients were demonstrated in 35 and 31% by CT and in 15 and 20% by PET. Liver imaging with MRI, CT, US, and PET in 41 patients showed liver in 49, 44, 41, and 27% patients, respectively. Bone metastases in 55 patients were demonstrated in 35% by PET, 40% by bone scintigraphy, and 40% by MRI; bone scintigraphy was complementary with MRI for axial lesions but superior for the detection of peripheral lesions. Ten patients had no imaged tumor site despite elevated calcitonin level (median 196 pg/ml; range 39-816). FDG uptake in neoplastic foci was higher in progressive patients but with a considerable overlap with stable ones. CONCLUSION: The most efficient imaging work-up for depicting MTC tumor sites would consist of a neck US, chest CT, liver MRI, bone scintigraphy, and axial skeleton MRI. FDG PET scan appeared to be less sensitive and of low prognostic value.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Bone Neoplasms/diagnosis/secondary, Bone and Bones/radionuclide imaging, Calcitonin/*blood, Carcinoma, Medullary/*metabolism/*pathology, Female, Fluorodeoxyglucose F18, Head and Neck Neoplasms/diagnosis/pathology, Humans, Image Processing, Computer-Assisted, Liver/pathology, Liver Neoplasms/diagnosis/secondary, Lung Neoplasms/diagnosis/secondary, Lymphatic Metastasis/diagnosis/pathology, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Recurrence, Local/diagnosis/pathology, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, Thyroid Neoplasms/*metabolism/*pathology, Tomography, X-Ray Computed, Whole-Body Counting
Open Access
Oui
Création de la notice
16/09/2016 11:14
Dernière modification de la notice
08/05/2019 17:33
Données d'usage